A prospective study of T- and B-lymphocyte subpopulations, CD81 expression levels on B cells and regulatory CD4+CD25+CD127 low/-FoxP3+ T cells in patients with chronic HCV infection during pegylated interferon-alpha2a plus ribavirin treatment

Journal of Viral Hepatitis

Volumn 18, Issue 6, 2011, Pages 384-392

  Soldevila, B ^a,b   Alonso, N ^a,b   Martinez Arconada M J ^a   Morillas, R M ^a,b   Planas, R ^a,b   Sanmarti A M ^a,b   Martinez Caceres E M ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

CD81; FoxP3; HCV; interferon alpha treatment; lymphocyte subpopulations; tregs

Indexed keywords

CD81 ANTIGEN; PEGINTERFERON ALPHA2A; RIBAVIRIN; TRANSCRIPTION FACTOR FOXP3; VIRUS RNA;

ADULT; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; DRUG WITHDRAWAL; FEMALE; FLOW CYTOMETRY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ADULT; ANTIGENS, CD; ANTIGENS, CD19; ANTIVIRAL AGENTS; B-LYMPHOCYTE SUBSETS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RIBAVIRIN; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 79955367218     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01317.x     Document Type: Article

References (42)

1. Bellentani W, Tiribelli C,. The spectrum of liver disease in the general population: lessons from the Dionysos study. J Hepatol 2001; 75: 531-537. (Pubitemid 32970415)
2. Hoofnagle JH,. Course and outcome of hepatitis C. Hepatology 2002; 36: S21-S29. (Pubitemid 35253460)
3. Strader DB, Wright T, Thomaw DL, Seeff LB,; American Association for the Study of Liver Diseases. Diagnosis, management and treatment of hepatitis C. Hepatology 2004; 39: 1147-1171.
4. Spengler U, Nattermann J,. Immunopathogenesis in hepatitis C virus cirrhosis. Clin Sci 2007; 112: 141-155.
5. Chang KM,. Immunopathogenesis of hepatitis C virus infection. Clin Liver Dis 2003; 7: 89-105.
6. Bowen DG, Walker CM,. Adaptative immune responses in acute and chronic hepatitis C virus infection. Nature 2005; 436: 946-952. (Pubitemid 41191670)
7. Ducoulombier D, Roque-Alfonso AM, Di Liberto G, et al. Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes. Hepatology 2004; 39: 817-825. (Pubitemid 38337663)
8. Roque-Alfonso AM, Ducoulombier D, Di Liberto G, et al. Compartmentalization of hepatitis C virus genotypes between plasma and peripheral blood mononuclear cells. J Virol 2005; 79: 6349-6357. (Pubitemid 40617238)
9. Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science 1998; 282: 938-941. (Pubitemid 28507525)
10. Wack A, Soldaini E, Tseng C, Nuti S, Klimpel G, Abrignani S,. Binding of the hepatitis C virus envelope rrotein E3 to CD81 provides a co-stimulatory signal for human T cells. Eur J Immunol 2001; 31: 166-175.
11. Zuckerman E,. Expansion of CD5 B-cell overexpressing CD81 in HCV infection: towards better understanding the link between HCV infection, B-cell activation and lymphoproliferation. J Hepatol 2003; 38: 674-677.
12. Zuckerman E, Slobodin G, Kessel A, et al. Peripheral B-cell CD5 expansion and CD81 overexpression and their association with disease severity and autoimmune markers in chronic hepatitis C virus infection. Clin Exp Immunol 2002; 128: 353-358. (Pubitemid 34534052)
13. Martin F, Roth DM, Jans DA, et al. Tetraspanins in viral infections: a fundamental role in viral biology? J Virol 2005; 79 (17): 10839-10851. (Pubitemid 41170627)
14. Fearon DT, Carter RH,. The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annu Rev Immunol 1995; 13: 127-149.
15. Kronenberger B, Rüster B, Elez R, et al. Interferon alfa down-regulates CD81 in patients with chronic hepatitis C. Hepatology 2001; 33 (6): 1518-1526. (Pubitemid 32496990)
16. Kronenberger B, Herrmann E, Hofmann P, et al. Dynamics of CD81 expression on lymphocyte subsets during interferon-α-based antiviral treatment of patients with chronic hepatitis C. J Leukoc Biol 2006; 80 (298): 298-308. (Pubitemid 44835503)
17. Chang LL, Cheng PN, Chel JS, Young KC,. CD81 down-regulation on B cells is associated with the response to interferon-alpha-based treatment for chronic hepatitis C virus infection. Antiviral Res 2007; 75: 43-51.
18. Shevach EM,. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 2006; 25: 195-201. (Pubitemid 44224153)
19. Rouse BT, Sarabgi PP, Suvas S,. Regulatory T cells in virus infections. Immunol Rev 2006; 212: 270-286.
20. Létourneau S, Krieg C, Pantaleo G, Boyman O,. IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. J Allergy Clin Immunol 2009; 123 (4): 758-762.
21. + Treg cells. J Exp Med 2006; 7: 1701-1711.
22. Hori S, Nomura T, Sakaguchi S,. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-1061. (Pubitemid 36222930)
23. Alatrakchi N, Koziel M,. Regulatory T cells and viral liver disease. J Viral Hepat 2009; 16 (4): 223-229.
24. Chang KM,. Regulatory T cells in hepatitis C virus infection. Hepatol Res 2007; 37: S327-S330.
25. Manigold T, Racanelli V,. T-cell regulation by CD4 regulatory T cells during hepatitis B and C virus infections: facts and controversies. Lancet Infect Dis 2007; 7: 804-813. (Pubitemid 350152043)
26. Dolganiuc A, Szabo G,. T cells with regulatory activity in hepatitis C virus infection: what we know and what we don't. J Leukoc Biol 2008; 84 (3): 614-622.
27. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526. (Pubitemid 36919874)
28. + T cells in chronic HCV patients undergoing combination antiviral therapy. J Hepatol 2008; 49 (3): 329-338.
29. Marinho RT, Pinto RM, Santos ML, de Moura MC,. Lymphocyte T helper-specific reactivity in sustained responders to interferon and ribavirin with negativization (seroconversion) of anti-hepatitis C virus. Liver Int 2004; 24: 413-418. (Pubitemid 40484553)
30. Trapero-Marugán M, García-Buey L, Muñoz C, et al. Sustained virological response to peginterferon plus ribavirin in chronic hepatiuis C genotype 1 patients associated a persistent Th1 immune response. Aliment Pharmacol Ther 2006; 24 (1): 117-128. (Pubitemid 43894012)
31. Barnes E, Harcourt G, Brown D, et al. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology 2002; 36 (3): 743-754. (Pubitemid 34977187)
32. Lin AW, Gonzalez SA, Cunningham-Rundles S, et al. CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection. Clin Exp Immunol 2004; 137 (2): 408-416. (Pubitemid 39013089)
33. Panasiuk A, Prokopowicz D, Zak J,. Immunological response in chronic hepatitis C virus infection during interferon alpha therapy. Hepatogastroenterology 2004; 51 (58): 1088-1092. (Pubitemid 38822476)
34. Cherukuri A, Carter RH, Brooks S, et al. B cell signaling is regulated by induced palmitoylation of CD81. J Biol Chem 2004; 279 (30): 31973-31982. (Pubitemid 39037872)
35. Maecker HT,. Human CD81 directly enhances Th1 and Th2 cell activation, but preferentially induces proliferation of Th2 cells upon long-term stimulation. BMC Immunol 2003; 4: 1.
36. high regulatory T cells during acute hepatitis C virus infection. J Infect Dis 2008; 197 (1): 46-57. (Pubitemid 351263465)
37. Cabrera R, Tt Z, Xu Y, et al. An immunomodulatory role for CD4 (+) CD25 (+) regulatory T lymophocytes in hepatitis C virus infection. Hepatology 2004; 40 (5): 1062-1071. (Pubitemid 39425561)
38. + T cells during chronic hepatitis C virus infection. J Virol 2005; 79: 7860-7867. (Pubitemid 40756821)
39. + regulatory T cells in hepatitis C virus infection. J Virol 2008; 82 (10): 5043-5053. (Pubitemid 351657064)
40. + T cells. Eur J Immunol 2007; 37: 129-138. (Pubitemid 46128793)
41. Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006; 203 (7): 1693-1700. (Pubitemid 44036275)
42. + T regulatory cell-mediated suppression. Immunity 2009; 30 (5): 636-645.